Chronic kidney disease (CKD) has a heritable component and is an important global public health problem because of its high prevalence and morbidity 1 . We conducted genome-wide association studies (GWAS) to identify susceptibility loci for glomerular filtration rate, estimated by serum creatinine (eGFRcrea) and cystatin C (eGFRcys), and CKD (eGFRcrea o 60 ml/min/1.73 m 2 ) in European-ancestry participants of four population-based cohorts (ARIC, CHS, FHS, RS; n ¼ 19,877; 2,388 CKD cases), and tested for replication in 21,466 participants (1,932 CKD cases). We identified significant SNP associations (P o 5 Â 10 À8 ) with CKD at the UMOD locus, with eGFRcrea at UMOD, SHROOM3 and GATM-SPATA5L1, and with eGFRcys at CST and STC1. UMOD encodes the most common protein in human urine, Tamm-Horsfall protein 2 , and rare mutations in UMOD cause mendelian forms of kidney disease 3 . Our findings provide new insights into CKD pathogenesis and underscore the importance of common genetic variants influencing renal function and disease.
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CKD affects 10-13% of US adults 4 . Estimates from Europe are similar 5 , and incidence and prevalence are increasing worldwide. Its most severe form, end-stage renal disease requires dialysis and currently affects over 500,000 US adults 6 . In addition to conferring risk for end-stage renal disease, CKD increases the risk of cardiovascular disease 7 and all-cause mortality 8 .
Multiple studies such as familial aggregation studies have provided evidence for a genetic component to kidney disease. Heritability estimates of eGFRcrea, the most commonly used measure of kidney function, are reported between 0.41 and 0.75 in individuals with the major CKD risk factors hypertension or diabetes 9, 10 , and as 0.33 in a population-based sample 11 . Heritability estimates of GFRcys are similar. Although rare genetic variants causing different forms of monogenetic kidney disease have been identified, common CKD susceptibility variants have been difficult to detect reproducibly by linkage or candidate gene studies 12 .
To discover such variants, we conducted meta-analyses of studyspecific GWAS for indices of renal function (eGFRcrea and eGFRcys) and for CKD from four population-based, unselected cohorts of the CHARGE Consortium 13 : Atherosclerosis Risk in Communities Study (ARIC), Cardiovascular Health Study (CHS), Framingham Heart Study (FHS) and Rotterdam Study (RS). As a direct measurement of kidney function is not feasible in population-based studies, we applied commonly used estimating equations to determine eGFRcrea 14 and eGFRcys 15 . Population-based measures of GFR are imperfect 16 , and using two different biomarkers to estimate GFR can therefore help to uncover true signals. CKD was defined as eGFRcrea o60 ml/min/1.73 m 2 according to US national guidelines 17 , as detailed in the Methods. Genotypes for 42.5 million SNPs were imputed within each study using reference genotype data from the HapMap CEU population. Study-specific details on genotyping and imputation are provided in Supplementary Table 1 online. SNPs showing evidence of suggestive (P o 4 Â 10 À7 ) or significant (P o 5 Â 10 À8 ) genome-wide association were tested for in silico replication in independent study samples: the Age Gene/Environment Susceptibility-Reykjavik Study (AGES) and the Women's Genome Health Study (WGHS). Detailed information on the study samples is provided in Supplementary Methods online.
Characteristics of the four discovery and two validation study samples are shown in Table 1 ; 19,877 participants with 2,388 CKD cases and 21,466 participants with 1,932 CKD cases contributed information, respectively. CKD prevalence was higher in cohorts with older participants, ranging from 6.3% (WGHS) to 24.3% (AGES). Characteristics among CKD cases are provided in Supplementary Table 2 online. Figure 1 summarizes meta-analysis results for CKD, eGFRcrea and eGFRcys across the discovery samples. The observed versus expected P-value distributions (quantile-quantile plots) are shown in Supplementary Figure 1 online: study-specific genomic inflation factors did not indicate substantial inflation of the test statistics for any of the traits. Table 2 lists the most significant SNP at each genomic locus associated with CKD, eGFRcrea and eGFRcys, and replication results. Study-specific results are presented in Supplementary Table 3 online.
For CKD, we identified SNP rs12917707 in a highly evolutionary conserved region 3.6 kb upstream of the UMOD (uromodulin) gene on chromosome 16 (P ¼ 5 Â 10 À16 across discovery and replication samples; Fig. 2 and Table 2 ). Seven SNPs in or upstream of UMOD in high LD (r 2 4 0.8) with rs12917707 were also associated with CKD at a genome-wide significant level. The minor T allele at rs12917707 was associated with 20% reduced risk of CKD (meta-analysis OR ¼ 0.80, P ¼ 2 Â 10 À12 ; Table 2 ). The association of rs12917707 with CKD, which was not significant in the FHS Study, showed some heterogeneity across studies (P heterogeneity ¼ 0.02). Findings were consistent in models adjusting for major CKD risk factors including systolic blood pressure, hypertension medication intake and diabetes mellitus, as well as stratified for age, sex, hypertension and diabetes status (Fig. 3) . Prospective information from the ARIC Study demonstrated that the T allele of rs12917707 was associated with a lower relative hazard of incident CKD (HR 0.81, 95% CI ¼ 0.72-0.92, P ¼ 0.001) over 14.7 years of follow-up (n ¼ 952 cases; see Methods). Rare UMOD mutations cause autosomal dominant forms of kidney disease, medullary cystic kidney disease type 2 (MCKD2), familial juvenile hyperuricemic nephropathy (FJHN), and glomerulocystic kidney disease (GCKD) (MIM603860, MIM162000, MIM609886) 3, 18, 19 . As the syndromes caused by rare UMOD mutations are often accompanied by hyperuricemia and gout, we explored the association of rs12917707 with these traits; no significant associations were observed. Although this does not exclude the presence of rare UMOD variants among our study participants, our study identifies another example of a genomic risk locus containing susceptibility variants across the spectrum of risk allele frequencies.
One study of Umod knockout mice reported 63% lower creatinine clearance in knockout compared to wild-type mice 20 . UMOD encodes the most abundant protein in the urine of healthy individuals, Tamm-Horsfall protein. The physiological functions of Tamm-Horsfall protein are not well understood but may include protection against inflammation and infection 2 . A possible role for UMOD in renal development was also recently reported 21 . UMOD is transcribed exclusively in renal tubular cells of the thick ascending limb of the loop of Henle. Our findings therefore suggest a common mechanism for CKD pathogenesis localized to the nephron's loop of Henle, which has previously received little attention. The major risk factors for kidney disease, hypertension and diabetes, are thought to affect the glomerulus primarily, and glomerular damage is typically characterized by albuminuria. Our findings, however, indicate that the association is consistent across strata of hypertension and diabetes, and we observed no association with albuminuria. Thus, our findings provide new insights into CKD pathogenesis and highlight the need to understand the production and functions of Tamm-Horsfall protein within the kidney. The broad CKD definition we chose, including a variety of causes of CKD such as hypertension and diabetes, indicates that the search for susceptibility variants for complex diseases may not only benefit from a narrower definition of the phenotype, but also from evaluation of a broad phenotype definition in order to identify common disease mechanisms.
Four loci were identified in association with eGFRcrea: the strongest association was for SNP rs12917707 at the UMOD locus (P overall ¼ 5 Â 10 À16 ; Table 2 ). The most significant SNP at the second significant eGFRcrea locus was the intronic SNP rs17319721 located in a highly evolutionary conserved region in SHROOM3 (shroom family member 3) on chromosome 4 (P overall ¼ 1 Â 10 À12 ; Fig. 2b and Table 2 ). The SHROOM3 gene product is expressed in human kidney and is reported to have a role in epithelial cell shape regulation 22 . The association at the third eGFRcrea locus, the intronic SNP rs6040055 in JAG1 (jagged 1) on chromosome 20 (P ¼ 1 Â 10 À8 ; Table 2 and Supplementary Fig. 2 online) , did not replicate (P overall ¼ 0.006). The finding may therefore be a false positive, although a biological role of JAG1 in kidney disease is supported by rare JAG1 mutations causing Alagille syndrome (MIM118450) 23 . Lastly, the intronic SNP rs2467853 in SPATA5L1 (spermatogenesis associated 5-like 1) at the GATM-SPATA5L1 locus on chromosome 15 was significantly associated with eGFRcrea (P overall ¼ 6 Â 10 À14 ; Fig. 2c and Table 2 ). GATM encodes glycine amidinotransferase, an enzyme involved in creatine biosynthesis. SNPs at this locus are therefore likely related to serum levels of creatinine without influencing susceptibility to kidney disease ( Table 3) . Although rs2467853 is located in SPATA5L1, strong LD extends into the region of the GATM gene.
We identified three loci in association with eGFRcys: the strongest association was for the intergenic SNP rs13038305 between CST3 (cystatin C) and CST9 (cystatin 9) (P ¼ 2.2 Â 10 À88 ; Fig. 2d and Table 2 ). SNPs within the cystatin (CST) superfamily gene cluster on chromosome 20 have been previously reported as associated with serum cystatin C levels 24 . The genes in the CST superfamily encode cystatin proteins. SNPs in these genes likely influence serum levels of cystatin C and therefore estimated eGFRcys, but not true GFR or CKD susceptibility (Table 3) . Second, we identified the intergenic SNP rs1731274, located 54 kb from the STC1 (stanniocalcin 1) gene on chromosome 8 (P ¼ 4.6 Â 10 À8 ; Fig. 2e and Table 2 ). STC1 encodes stanniocalcin 1, a hormone regulating calcium homeostasis in fish. In mammals, it is highly expressed in the renal nephron and may influence local calcium and phosphate homeostasis through a paracrine mechanism 25 . A recent study in STC1 transgenic mice reported STC1 as a renal protective protein with a potent anti-inflammatory role 26 . As the replication samples did not have cystatin C measurements available, we explored the association of rs1731274 with eGFRcrea across the discovery and replication samples (P ¼ 2 Â 10 À7 , Table 2 ). Finally, rs12917707 at the UMOD locus was associated with eGFRcys at P ¼ 2 Â 10 À7 . Table 3 presents the association of all genome-wide significant SNPs across the three renal traits. SNPs in UMOD, SHROOM3 and STC1 showed direction-consistent association across traits. For example, rs12917707 at UMOD was associated with both higher eGFRcrea and eGFRcys representing better kidney function, and with lower odds of CKD, conferring disease protection. SNPs at the GATM-SPATA5L1 and CST regions were only associated with the respective discovery trait; the association of rs2467853 at the GATM-SPATA5L1 locus with CKD likely results from the eGFRcreabased definition of CKD. All SNPs associated with CKD, eGFRcrea and eGFRcys at P o 4 Â 10 À7 are listed in Supplementary Tables 4, 5 and 6 online, respectively.
Together, loci for eGFRcrea explain 0.7% of the eGFRcrea variance (0.43% without the GATM locus), and loci for eGFRcys explain 3.2% of the eGFRcys variance (0.24% without the CST locus), suggesting that additional yet-undiscovered genetic variants influence variability in renal function. In accordance with small absolute differences observed in other GWAS for continuous human traits, the multivariable adjusted eGFR difference across genotypes for any one locus was small. As risk alleles may act in an additive fashion, we created a risk score for each individual as the sum of risk alleles at UMOD, SHROOM3 and STC1. These analyses were conducted in the ARIC study, the largest individual study contributing data and with available prospective information. The mean eGFRcrea was 10 ml/min/1.73 m 2 lower in individuals with all six risk alleles across the three loci Meta-analysis P values are adjusted for the trait-and study-specific genomic-control parameters (see Supplementary Fig. 1 ). For eGFR, betas indicate the change in eGFR per minor allele for the natural logarithmic transformation of eGFR. NA: eGFRcys was not available in the replication samples, but rs1731274 was associated with eGFRcrea after replication at P ¼ 2 Â 10 À7 , beta ¼ -0.009, s.e. ¼ 0.002. OE var ratio: sample-size weighted mean of the observed by expected variance ratio for each SNP across the discovery samples; MAF: minor allele frequency, sample-size weighted mean of MAF across the discovery samples. SNP position based on dbSNP129.
compared to those with no risk alleles (P ¼ 2 Â 10 À8 per unit score increase). CKD prevalence ranged from 0% in those without any risk alleles to 12.1% in individuals carrying all six risk alleles. In summary, we have identified and validated common variants at several previously unknown loci conferring susceptibility for kidney dysfunction and CKD in large, unselected populationbased studies. Studies to understand the production and functions of Tamm-Horsfall protein are warranted and may eventually lead to novel prevention and intervention options to reduce CKD risk.
METHODS
Study samples. Four large, population-based cohorts of the CHARGE consortium had GWAS data available and formed the discovery sample: ARIC, CHS, FHS and RS. Detailed information about these cohorts, including the design papers, is provided in the Supplementary Methods. Briefly, the studies were initiated to study cardiovascular disease and its risk factors and diseases related to aging. Genotyping and imputation. Detailed information about genotyping and imputation methods is provided in Supplementary Table 1 , and details about data cleaning are provided in the Supplementary Methods. Briefly, all studies directly genotyped between 300,000 and 900,000 SNPs using whole-genome genotyping arrays by either Affymetrix (6.0, ARIC; 500K and 50K gene-centric, eGFRcrea, eGFRcys and CKD. Serum creatinine was measured using a modified kinetic Jaffe reaction in all studies but AGES, where an enzymatic method was used. eGFRcrea was calculated using the Modification of Diet in Renal Disease (MDRD) Study equation 14 : eGFRcrea (ml/min/1.73 m 2 ) ¼ 186.3 Â serum creatinine (mg/dl) À1.154 Â age À0.203 Â 0.742 (if female). To be comparable across studies, creatinine values in all studies were calibrated using regression to age-and sex-adjusted mean values from a nationally representative US survey as described previously 28 . Cystatin C was measured by a particleenhanced immunonephelometric assay (N Latex Cystatin C, Dade Behring) at ARIC visit 4, CHS baseline exam, and FHS offspring exam 7 with a nephelometer (BNII, Dade-Behring). eGFRcys was then calculated using the formula eGFRcys ¼ 76.7 Â (serum cystatin C) À1. 19 (ref. 15) . CKD was defined as eGFRcrea o60 ml/min/1.73 m 2 according to National Kidney Foundation guidelines 17 .
CKD in CHS, RS, WGHS and AGES was defined on the basis of a single measurement of serum creatinine at the baseline visit. FHS and ARIC used a cumulative definition of CKD based on serum creatinine measurements at several study visits as detailed in the Supplementary Methods. Incident CKD in ARIC was defined as eGFRcrea o60 ml/min/1.73 m 2 at study visits 2 or 4 in individuals with eGFRcrea Z60 ml/min/1.73 m 2 at study visit 1, or a kidney-disease specific ICD code on a hospital discharge record or death certificate from study inception in 1987 through January 1, 2005 (ref. 29) .
Information on age and sex was collected at each study visit, and ancestry was self-reported. Potential population stratification was assessed as detailed in the Supplementary Methods. Statistical analysis. GWAS was conducted within each cohort for eGFRcrea, eGFRcys and CKD, followed by meta-analysis of the study-specific associations for each trait. SNPs showing genome-wide significant association with any of the three traits in meta-analyses were then explored for their association with the other two traits.
The phenotype for the eGFR analyses in all studies was created by calculating a natural logarithmic transformation of eGFR obtained from the respective equations for eGFRcrea and eGFRcys. All studies but CHS then created sex-specific age-and study-site (ARIC) or cohort (FHS) adjusted residuals. CHS adjusted for age, sex and study site in multivariable regression models. Incident CKD in ARIC was analyzed using multivariable-adjusted Cox proportional hazards regression. Software packages used by the individual studies to conduct linear and logistic regression are listed in Supplementary Table 1 . FHS accounted for the relatedness of individuals in the analyses as detailed in the Supplementary Methods. Pedigree correlations were adjusted using the robust variance option. All studies used an additive genetic model.
Meta-analysis was conducted using inverse-variance weighting as implemented in METAL (see URLs section below). Prior to meta-analysis, the genomic control parameter was calculated within each study for each trait to assess potential inflation of the test statistics. If the parameter was larger than 1, an adjustment was carried out. Only SNPs with minor allele frequency (MAF) Z2% were analyzed based on the number of CKD cases, corresponding to approximately 50 carriers of the minor allele with CKD. Statistical heterogeneity was evaluated using Cochrane's w 2 test (Q-test).
The most significant SNPs at genomic loci with evidence of suggestive association (P o 4 Â 10 À7 ) for any of the traits were tested for replication in the independent samples. This threshold corresponds to 1/2.5 million tests conducted and corresponds to one or less expected false-positive findings 30 . A threshold of P o 5 Â 10 À8 was used to indicate genome-wide significance, corresponding to a Bonferroni correction for the estimated 1 million common independent SNPs across the genome (0.05/1 million). The SNAP program with the HapMap CEU sample as a reference was used to identify the best proxy in the WGHS dataset, to evaluate LD to nearby coding SNPs, and to evaluate LD between imputed SNPs and proxy SNPs that were directly genotyped.
URLs. MACH, http://www.sph.umich.edu/csg/abecasis/MACH/; METAL, http: //www.sph.umich.edu/csg/abecasis/Metal/index.html; SNAP, http://www.broad. mit.edu/mpg/snap/ldsearch.php.
Note: Supplementary information is available on the Nature Genetics website.
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